63 results match your criteria: "Hospital Clínico Universitario Virgen de la Arrixaca-IMIB[Affiliation]"
Phys Med Biol
December 2024
Hospital Clínico Universitario Virgen de la Arrixaca-IMIB, ctra. Madrid-Cartagena, 30120 El Palmar (Murcia), Spain.
. For calculating shielding in x-ray rooms, it is often assumed that the beams impinge perpendicularly on the protective barriers. This is not always true, but this premise simplifies the calculations and enhances protection by being a conservative calculation.
View Article and Find Full Text PDFJ Am Coll Cardiol
October 2024
Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas-CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. Electronic address:
Background: Coagulase-negative staphylococci (CoNS) are an increasingly common cause of infective endocarditis (IE) and lack recent data from large studies.
Objectives: Our aim was to describe the epidemiology, clinical characteristics, and outcomes of staphylococcal IE in a contemporary nationwide cohort study, while comparing coagulase-negative staphylococcal IE (CoNSIE) to IE from Staphylococcus aureus (SAIE), and among IE caused by Staphylococcus epidermidis (SE), S. lugdunensis (SL), and other CoNS.
Ther Adv Neurol Disord
October 2024
Clinical Neuroimmunology Unit and CSUR Multiple Sclerosis, Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca (IMIB-Arrixaca)/Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, Universidad Católica San Antonio, Murcia, Spain.
Recent advances in multiple sclerosis (MS) management have shifted perspectives on treatment strategies, advocating for the early initiation of high-efficacy disease-modifying therapies (heDMTs). This perspective review discusses the rationale, benefits, and challenges associated with early heDMT initiation, reflecting on the obsolescence of the traditional "first-line" and "second-line" treatment classifications. The article emerges from the last update of the consensus document of the Spanish Society of Neurology on the treatment of MS.
View Article and Find Full Text PDFNeurology
September 2024
From the Neuroimmunology Program (E.F., G.O.-C., E.M.-H., M.G., E.C., J.M.C.-M., S.L., Y.B., A.S., J.D., M.S., T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Pediatric Neuroimmunology Unit (E.F., V.G.-Á., V.D., T.A.), Neurology Department, Sant Joan de Déu Children's Hospital, and Sant Joan de Déu Private Foundation for Research and Education (IRSJD) Sant Joan de Déu Children's Hospital (E.F.), University of Barcelona; Pediatric Neurology Department (G.O.-C.), Hospital Parc Taulí de Sabadell; Immunology Service (L.N., R.R.G.), Hospital Clinic, and Ophtalmology Service (G.R., C.d.-P.-S.), Sant Joan de Déu Children's Hospital, University of Barcelona; Department of Neurology (J.B.-L.), University Hospital "12 de Octubre"; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) (J.B.-L.); Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED) (J.B.-L.); Department of Medicine, Faculty of Medicine (J.B.-L.), Complutense University, Madrid; Neurology Service (C.I.), Hospital Clínico Universitario, Zaragoza; Neurology Service (J.M.G.D.), Hospital General Universitario Gregorio Marañón, Madrid; Neurology Service (C.C.), Hospital Universitario Son Espases, Palma de Mallorca; Neurology Service (A.C.), Hospital de Mataró, Barcelona; Unit of Neuroimmunology and Multiple Sclerosis of Girona (UNIEMTG) (G.Á.B.), Department of Neurology, University Hospital Dr. Josep Trueta of Girona; Neurology Service (I.G.-S.), Hospital Álvaro Cunqueiro, Vigo; Department of Neurology (C.O.-G.), Hospital Clinico San Carlos, IdISSC, Madrid; Departament of Medicine (C.O.-G.), Medicine Faculty, Universidad Complutense de Madrid (UCM); Neurology Service (M.R.), Hospital Parc Taulí, Sabadell, Barcelona; Multiple Sclerosis CSUR and Clinical Neuroimmunology Unit (J.M.-P., J.E.M.-L.), Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca (IMIB-Arrixaca), Clinical Neuroimmunology and Multiple Sclerosis Cathedra, UCAM, Universidad Católica San Antonio de Murcia; Neurology Service (L.B.C.), Hospital Universitario Fundación Alcorcón, Madrid; Neurology Service (J.M.-M.), Hospital Universitario Miguel Servet, Zaragoza; Neurology Service (M.P., J.G.), Complejo Hospitalario Universitario de Albacete; Neurology Service (R.V.-G.), Hospital Universitario JM Morales Meseguer, Internal Medicine Department, Universidad de Murcia, Spain; Department of Neurology (J.D.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institution for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain.
Background And Objectives: The 2023 criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) perform well in adults but have not been assessed in children.
Methods: This prospective observational nationwide study includes children and adults with demyelinating syndromes or encephalitis, whose serum or CSF was found MOG-immunoglobulin G (IgG) positive at Institut d'Investigacions Biomèdiques August Pi i Sunyer-Hospital Clínic of Barcelona (Spain). Exclusion criteria were lack of clinical information and follow-up <1 year, and serum unavailable for antibody testing.
Front Transplant
November 2023
Unidad HPB y Trasplante Hepático, Servicio de Cirugía General y Digestiva, Hospital Universitari de Bellvitge, Barcelona, Spain.
Thoracoabdominal (TA) normothermic regional perfusion (NRP) should allow the safe recovery of heart and liver grafts simultaneously in the context of controlled donation after circulatory death (cDCD). We present the initial results of cDCD liver transplantation with simultaneous liver and heart procurement in Spain until October 2021. Outcomes were compared with a matched cohort of cDCD with abdominal NRP (A-NRP) from participating institutions.
View Article and Find Full Text PDFCirculation
June 2024
Servei de Cardiologia (A.E., L.G.-G., G.T.-T., A.R.-M., M.A.C., H.C.-C., I.F.-G., J.F.R.-P.), Hospital Universitari Vall d´Hebron, Barcelona, Spain.
Background: Ascending aorta dilation and aortic valve degeneration are common complications in patients with bicuspid aortic valve. Several retrospective studies have suggested the benefit of statins in reducing these complications. This study aimed to determine whether atorvastatin treatment is effective in reducing the growth of aortic diameters in bicuspid aortic valve and if it slows the progression of valve calcification.
View Article and Find Full Text PDFNeurologia (Engl Ed)
March 2024
Departamento de Neurología, Hospital Clínico San Carlos, IdISSC, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain.
The last consensus statement of the Spanish Society of Neurology's Demyelinating Diseases Study Group on the treatment of multiple sclerosis (MS) was issued in 2016. Although many of the positions taken remain valid, there have been significant changes in the management and treatment of MS, both due to the approval of new drugs with different action mechanisms and due to the evolution of previously fixed concepts. This has enabled new approaches to specific situations such as pregnancy and vaccination, and the inclusion of new variables in clinical decision-making, such as the early use of high-efficacy disease-modifying therapies (DMT), consideration of the patient's perspective, and the use of such novel technologies as remote monitoring.
View Article and Find Full Text PDFJ Clin Lab Anal
December 2023
Grup de Recerca Translacional en Neoplàsies Hematològiques, Cancer Research Programme, IMIM-Hospital del Mar, Barcelona, Spain.
Background: Previous investigations pointed out a role for antigen stimulation in Sezary syndrome (SS). High-throughput sequencing of the T cell receptor (TR) offers several applications beyond diagnostic purposes, including the study of T cell pathogenesis.
Methods: We performed high-throughput RNA sequencing of the TR alpha (TRA) and beta (TRB) genes focusing on the complementarity-determining region 3 (CDR3) in 11 SS and one erythrodermic mycosis fungoides (MF) patients.
Neurol Ther
December 2023
Neurology Service, Hospital Universitario Basurto, Bilbao, Spain.
Introduction: Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing-remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinical trials and a real-world setting on efficacy, tolerability and patient-reported benefits. The TERICARE study assessed the impact of teriflunomide treatment over 2 years on health-related quality of life (HRQoL) and some of the most common and disabling symptoms of MS, such as fatigue and depression.
Methods: This prospective observational study in Spain included RRMS patients treated with teriflunomide for ≤ 4 weeks.
Phys Med Biol
December 2023
Hospital Clínico Universitario Virgen de la Arrixaca-IMIB, ctra. Madrid-Cartagena, E-30120 El Palmar (Murcia), Spain.
An appropriate parameter to study the performance of an x-ray imaging system is contrast transfer, or the system's ability to capture contrast in the radiation beam and bring it to the image. However, determining the input contrast to the system is difficult, as it is heavily affected by secondary radiation, which in turn depends on a multitude of factors. This work presents a method to improve the calculation of input contrast to the imaging system when PMMA phantoms are used.
View Article and Find Full Text PDFNefrologia (Engl Ed)
November 2023
Proyecto Colaborativo Internacional Donante, Murcia, Spain; Departamento de Psicología, Universidad Católica de Murcia, UCAM, Murcia, Spain.
J Clin Oncol
June 2023
Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
Purpose: The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated.
Patients And Methods: An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM. The clinical significance of the algorithm was tested and validated in 488 patients with smoldering MM, 3,870 patients with active MM and 211 patients with AL amyloidosis.
Comput Biol Med
March 2023
Departamento de Teoría de la Señal y Comunicaciones y Sistemas Telemáticos y Computación, Universidad Rey Juan Carlos, Madrid, Spain; D!lemmaLab Ltd Startup, Fuenlabrada, Spain.
Background/aim: In atrial fibrillation (AF) ablation procedures, it is desirable to know whether a proper disconnection of the pulmonary veins (PVs) was achieved. We hypothesize that information about their isolation could be provided by analyzing changes in P-wave after ablation. Thus, we present a method to detect PV disconnection using P-wave signal analysis.
View Article and Find Full Text PDFLeuk Lymphoma
March 2023
Department of Hematology, Hospital Universitari Vall d´Hebron, Barcelona, Spain.
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases without a care standard and show variability in treatment outcomes. This Spanish, observational, prospective study ERASME (CEL-SMD-2012-01) assessed the evolution of newly diagnosed and treatment-naïve high-risk MDS patients (according to IPPS-R). 204 patients were included: median age 73.
View Article and Find Full Text PDFBMC Cancer
December 2022
GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients.
Methods: HER2-negative ABC patients received 21-day cycles of pembrolizumab 200 mg (day 1) and gemcitabine (days 1 and 8). A run-in-phase (6 + 6 design) was planned with two dose levels (DL) of gemcitabine (1,250 mg/m [DL0]; 1,000 mg/m [DL1]) to determine the recommended phase II dose (RP2D).
Neurologia (Engl Ed)
October 2022
Centro de Esclerosis Múltiple de Cataluña (Cemcat), Servicio de Neurología/Neuroinmunología, Hospital Universitario Vall de Hebrón, Barcelona, Spain.
Introduction: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis.
Objective: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain.
Development: A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017.
Front Cardiovasc Med
July 2022
University of Strasbourg, INSERM, UMR 1260, Nanoregenerative Medicine, Strasbourg, France.
Heart failure (HF) and cancer are responsible for 50% of all deaths in middle-aged people. These diseases are tightly linked, which is supported by recent epidemiological studies and case control studies, demonstrating that HF patients have a higher risk to develop cancer such as lung and breast cancer. For HF patients, a one-size-fits-all clinical management strategy is not effective and patient management represents a major economical and clinical burden.
View Article and Find Full Text PDFMed Phys
January 2023
Hospital Clínico Universitario Virgen de la Arrixaca - IMIB, ctra. Madrid-Cartagena, El Palmar, Murcia, Spain.
Purpose: To describe the scattered radiation spectra inside an x-ray room for different scattering conditions.
Methods: Monte Carlo simulations of an x-ray room using phantoms of different size, varying field sizes, and a range of mono-energetic beams were carried out. For each energy, the particle fluence spectrum of scattered photons was collected at different spherical zones to describe the radiation reaching the different boundaries of the x-ray room.
Thromb Haemost
October 2022
Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major bleeding events (especially intracranial bleeds) may still occur and be devastating. The decision for initiating and continuing anticoagulation is often based on a careful assessment of both thromboembolism and bleeding risk. The more common and validated bleeding risk factors have been used to formulate bleeding risk stratification scores, but thromboembolism and bleeding risk factors often overlap.
View Article and Find Full Text PDFEur J Cancer
June 2022
GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Institut Català D'Oncologia (ICO) & IDIBELL, L'Hospitalet, Barcelona, Spain.
Background: An earlier analysis of the PEARL phase III study showed that palbociclib plus endocrine therapy (ET) does not improve progression-free survival (PFS) over capecitabine in aromatase inhibitor-resistant, hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) patients. Here, we report the final overall survival (OS) analysis.
Methods: Postmenopausal patients (N = 601) were randomized 1:1 to capecitabine or palbociclib plus ET (exemestane, Cohort 1; fulvestrant, Cohort 2).
Europace
November 2022
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool, UK.
Whilst there is a clear clinical benefit of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major bleeding events (especially intracranial bleeds) may still occur and be devastating. The decision to initiate and continue anticoagulation is often based on a careful assessment of both the thromboembolism and bleeding risk. The more common and validated bleeding risk factors have been used to formulate bleeding risk stratification scores, but thromboembolism and bleeding risk factors often overlap.
View Article and Find Full Text PDFSci Rep
August 2021
Arrhythmia Unit, Cardiology Department, Hospital de Basurto, Bilbao, Spain.
Cryoablation is safe and effective for the treatment of atrial fibrillation (AF) in controlled clinical trials, but contemporary real-world usage and outcomes are limited. The Report of the Spanish Cryoballoon Ablation Registry (RECABA) was designed to evaluate acute and 12-month outcomes of cryoballoon ablation for the treatment of AF in Spain. Patients from 27 Spanish centers were prospectively enrolled.
View Article and Find Full Text PDFAn Pediatr (Engl Ed)
July 2021
Genética Médica, Servicio de Pediatría, Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca, Murcia, España.
Introduction: For more than a decade, after the ECTRIMS Congress, Spain has hosted the Post-ECTRIMS meeting, where neurologists with expertise in multiple sclerosis (MS) meet to review the new developments presented at the ECTRIMS.
Aim: This article, published in two parts, summarises the presentations of the post-ECTRIMS meeting, held online on 16 and 17 October 2020.
Development: This second part highlights the importance of gender and age in understanding the pathology of the disease and optimising its management.
Introduction: For more than a decade, following the ECTRIMS Congress, the Post-ECTRIMS Meeting has been held in Spain, where neurologists with expertise in multiple sclerosis (MS) from all over the country meet to review the most relevant latest developments presented at the ECTRIMS congress (on this occasion held together with ACTRIMS).
Aim: This article, published in two parts, summarises the presentations that took place at the Post-ECTRIMS Meeting, held online on 16 and 17 October 2020.
Development: This first part includes the latest results regarding the impact of the environment and lifestyle on risk of MS and its clinical course, and the role of epigenetics and genetic factors on these processes.